Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Researchers from University of Lubeck, Medical Department describe findings in cancer vaccines
January 27th, 2009
According to recent research from Lubeck, Germany, "Wood and colleagues present the results from a randomized phase III trial comparing adjuvant vitespen therapy with observation alone following nephrectomy for the treatment of kidney cancer. The primary end point, recurrence-free survival, was similar in both groups." "Although patients with early-stage kidney cancer tended to have improved recurrence-free survival compared with the observation group, the difference was not significant. Results for the secondary end point, overall survival, were not mature, and patients continue to be followed up. Five other randomized trials of adjuvant immunotherapy for kidney cancer...
Source: Cancer Weekly (2009-01-27)
|
